Back to search results

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

This study is testing two types of computerized cognitive training to help breast cancer survivors who are experiencing problems with their thinking and memory, often called cancer-related cognitive impairment. You could be eligible if you are a breast cancer survivor (Stage I-III, not spread to other parts of the body) between 18 and 100 years old, and have reported some cognitive (thinking) difficulties. The study wants to see if these training programs can improve how you feel about your cognitive abilities. We don't know the current recruitment status from this record.

Study design
This is a Phase III, double-blind, randomized controlled trial comparing two types of computerized cognitive training with a planned enrollment of 386 participants.
What's involved
Participants will engage in one of two computerized cognitive training programs: either "Global Stimulation Games" or "Neuroplasticity Games."
Compensation
Not stated in the trial record.
Follow-up
Your self-reported cognitive impairment will be measured 12 weeks after you start the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05896189

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Active, Not Recruiting
NAAges 18+InterventionalPrevention
NRG Oncology
~386 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:Arm 1: Computerized Cognitive Training-Global Stimulation GamesArm 2: Computerized Cognitive Training-Neuroplasticity Games

At a glance

Recruiting sites
0 of 680 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Self-reported perceived cognitive impairment measured-post intervention
Measured over 12 weeks from randomization

Conditions

Breast Cancer
Cognitive Impairments

Explore related trials

Breast CarcinomaCognitive Dysfunction

Where it's being run

680 sites across 41 states
Michigan86
Illinois59
California57
Ohio51
Minnesota43
Pennsylvania30
Kansas29
Missouri28

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.
The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.
The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.
Participants must be at least 6 months and no more than 5 years (after completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4/6, or immunotherapy). Participants may still be taking endocrine therapy and/or trastuzumab.
The participant must be able to understand, speak, read, and write in English or Spanish.

Exclusion

Scoring less than or equal to 3 on the 6-item cognitive screen.
Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3.
Definitive clinical or radiologic evidence of metastatic disease.
Current or past history of another cancer. Patients with history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible.
Previous exposure to chemotherapy treatment for another cancer or due to other medical condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis).
Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involved surgery.
Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer's disease or other dementia.
Participants with active substance abuse and/or in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.
Participants who are enrolled in an active behavioral intervention (e.g., occupational therapy, physical therapy, etc.) or pharmaceutical intervention or who are in the follow-up phase of a cancer control trial or therapeutic trial that has extensive PRO follow-up after treatment ends. Participants who are enrolled in a therapeutic trial in which they have completed active treatment and require only minimal follow-up monitoring of toxicity and/or survival analysis (cancer-related mortality or all-cause mortality) would be eligible.
Hearing impairment unless adequately corrected with hearing aids to be able to hear over the phone for the neuropsychological testing.

What this trial measures

  • Self-reported perceived cognitive impairment measured-post intervention12 weeks from randomization

    FACT-Cog PCI scale score (Functional Assessment of Cancer Therapy-Cognitive Function-perceived cognitive impairment)